Currently Viewing:
Newsroom
Currently Reading
GSK Reports Positive Findings for COPD Treatment Studies
October 25, 2015 – AJMC Staff
5 Things to Know About 340B
October 23, 2015 – Surabhi Dangi-Garimella, PhD
Harvard Researchers Identify Racial Disparity in Care of Cancer Patients on Medicare
October 23, 2015 – Surabhi Dangi-Garimella, PhD
Urology Cancer Patients Faced Neglect at Arizona VA Hospital
October 22, 2015 – Surabhi Dangi-Garimella, PhD
Onivyde Approved for Advanced Pancreatic Cancer
October 22, 2015 – AJMC Staff
ERLS Improves Functional Status Post Oncologic Liver Surgery
October 22, 2015 – Surabhi Dangi-Garimella, PhD
The Benefit of Marrying PROs With Coordinated Care in Advanced Cancer Patients
October 21, 2015 – Surabhi Dangi-Garimella, PhD
Do Surrogate Endpoints Fail the Litmus Test?
October 21, 2015 – Surabhi Dangi-Garimella, PhD
American Cancer Society Now Recommends Delayed and Less Frequent Screening Mammograms
October 20, 2015 – Surabhi Dangi-Garimella, PhD

GSK Reports Positive Findings for COPD Treatment Studies

AJMC Staff
Two head-to-head trials comparing the safety of Incruse Ellipta to 2 available bronchodilator treatments used by patients with chronic obstructive pulmonary disease has yielded positive results for GlaxoSmithKline's therapy.
Two head-to-head trials comparing the safety of Incruse Ellipta (umeclidinium) to 2 available bronchodilator treatments used by patients with chronic obstructive pulmonary disease (COPD) has yielded positive results for GlaxoSmithKline’s therapy.

In 12-week multi-center, randomized, blinded study of 1259 patients, the once-daily 62.5 mcg dose of umeclidinium achieved a statistically significant improvement in lung function as 12 weeks compared to a once-daily 18 mcg dose of tiotropium.

The second study was a 12-week multi-center, non-US, randomized, open-label study, which found that the once-daily 62.5 mcg dose of umeclidinium was non-inferior to a once-daily 44 mcg dose of glycopyrronium.

The most common side effects for all 3 treatments were headache and nasopharyngitis.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up